|
KMID : 1094020160330040187
|
|
Journal of Veterinary Clinics
2016 Volume.33 No. 4 p.187 ~ p.193
|
|
|
Tyrosine Kinase Inhibitor as Clinical Application Feasibility in Canine Intractable Tumor Diseases
|
|
Choi Eul-Soo
Song Joong-Hyun
An Su-Jin
Cho Kyu-Woan
Jung Dong-In
Shin Jong-Il
Sur Jung-Hyang
Kang Byeong-Teck
|
|
|
Abstract
|
|
|
|
A tyrosine kinase is an enzyme that can transfer a phosphate group from ATP to a protein in a cell. Itfunctions as an "on" or "off" switch in many cellular functions. This study aims to show that the actions of growthfactors associated with PDGFR-α, PDGFR-β, VEGFR-2, c-KIT, and c-ABL, which are used in veterinary medicine,are expressed in canine intractable tumors. This study used archival cases of canine paraganglioma, gastrointestinaladenocarcinoma, hepatocellular carcinoma, and renal cell carcinoma. Tissues had been immunohistochemical analysis. The antibodies used were PDGFR-α, PDGFR-β, c-kit, VEGFR-2, and c-Abl. PDGFR-α was expressed only in HCC,and PDGFR-β was expressed in all tumors. VEGFR was also only expressed in HCC, and c-KIT has been expressedin HCC, paraganglioma, and small intestinal adenocarcinoma. c-Abl was expressed in all cancers, but was weaklyexpressed in paraganglioma, while more than moderately expressed in other tissues. In conclusion, this study investigatedhow TKIs used in human medicine can be applied to canine intractable tumors, through immunohistochemistry. Theresults indicate that there may be an application for TKIs in treating canine intractable tumors.
|
|
|
KEYWORD
|
|
|
umor, dog, tyrosine kinase inhibitor, immunohistochemistry
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|